Organism Function – Page 6

Aerovate Therapeutics’ Shares Plummet 93.3% After Disappointing IMPAHCT Study Results for AV-101 in Pulmonary Arterial Hypertension

1 year ago talkbio0Tagged 4-aminohippuric acid, Aerovate, AV-101, Biotech Stocks, Clinical Trials, Drug Formulation Process, imatinib, IMPAHCT, Inspiration function, Pulmonary arterial hypertension

Aerovate Therapeutics, AV-101, IMPAHCT Study, Pulmonary Arterial Hypertension, PAH, Imatinib, Inhaled Formulation, Biotech Stocks, Clinical Trials

Syntis Bio Launches Revolutionary Oral Therapy to Mimic Weight-Loss Surgery

1 year ago talkbio0Tagged Bio, Diabetes, Digestion, drug absorption, gastric bypass surgery, Intestines, Metabolic Control, Obesity, Oral Therapy, SYNT-101, Syntis, weight-loss surgery

Syntis Bio, weight-loss surgery, oral therapy, obesity, diabetes, rare diseases, SYNT-101, gastric bypass surgery, small intestine, metabolic control, digestion, drug absorption.

Senate Fails to Pass Bill Codifying Access to Contraception Amid Republican Opposition

1 year ago talkbio0Tagged Birth, Contraceptive methods, Control Groups, Gegenhalten, Republican, rights, Senate, Voting

Contraception, Senate Vote, Republican Opposition, Reproductive Rights, Birth Control

Repare Backer Amplitude Ventures Launches $192M Biotech Fund for Development and Growth

1 year ago talkbio0Tagged Amplitude, biotech fund, Biotechnology, development aspects, Growth, Investments, Repare, Ventures

Amplitude Ventures, biotech fund, Repare Therapeutics, development, growth, investment, biotechnology

Ozempic Reduces Mortality Risk by 20% in Diabetes Patients with Chronic Kidney Disease

1 year ago1 year ago talkbio0Tagged Cardiovascular system, Cessation of life, Chronic Kidney Diseases, Diabetes, Failure (biologic function), Kidney, Mortality Vital Statistics, Nordisk, Obesity, semaglutide, Wegovy

** Ozempic, Novo Nordisk, diabetes, chronic kidney disease, mortality risk, cardiovascular deaths, kidney failure, semaglutide, Wegovy, obesity treatment

J&J Adjusts Dosing Strategy for Actinium Prostate Cancer Drug Following Early Study Setbacks

1 year ago talkbio0Tagged Actinium, Cancer Therapeutic Procedure, Cessation of life, Clinical Trials, dosing, Drug Development, Flexible, J&J, Johnson & Johnson, Malignant neoplasm of prostate

J&J, Johnson & Johnson, actinium prostate cancer drug, capped dosing, flexible dosing, patient deaths, early study, clinical trial, cancer treatment, drug development.